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Abstract
The PI3K/AKT/mTOR pathway has frequently been found activated in human tumors. We show that in addition to Wnt
signaling dysfunction, the PI3K/AKT/mTOR pathway is often upregulated in mouse Msh22/2 initiated intestinal tumors. NVP-
BEZ235 is a dual PI3K/mTOR inhibitor toxic to many cancer cell lines and currently involved in clinical trials. We have treated
two mouse models involving Msh2 that develop small intestinal and/or colonic tumors with NVP-BEZ235, and a subset of
animals with NVP-BEZ235 and MEK inhibitor ADZ4266. The disease phenotype has been followed with pathology, 18F FDG
PET imaging, and endoscopy. Intestinal adenocarcinomas are significantly decreased in multiplicity by both drug regimens.
The majority of tumors treated with combined therapy regress significantly, while a small number of highly progressed
tumors persist. We have examined PTEN, AKT, MEK 1&2, MAPK, S6K, mTOR, PDPK1, and Cyclin D1 and find variable
alterations that include downregulation of PTEN, upregulation of AKT and changes in its phosphorylated forms,
upregulation of pMEK 1&2, p42p44MAPK, pS6K, and Cyclin D1. Apoptosis has been found intact in some tumors and not in
others. Our data indicate that NVP-BEZ235 alone and in combination with ADZ4266 are effective in treating a proportion of
colorectal cancers, but that highly progressed resistant tumors grow in the presence of the drugs. Pathways upregulated in
some resistant tumors also include PDPK1, suggesting that metabolic inhibitors may also be useful in treating these tumors.
Citation: Kucherlapati MH, Esfahani S, Habibollahi P, Wang J, Still ER, et al. (2013) Genotype Directed Therapy in Murine Mismatch Repair Deficient Tumors. PLoS
ONE 8(7): e68817. doi:10.1371/journal.pone.0068817
Editor: Partha Mukhopadhyay, National Institutes of Health, United States of America
Received December 31, 2012; Accepted June 4, 2013; Published July 23, 2013
Copyright:  2013 Kucherlapati et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work in this study was supported by a grant from the National Cancer Institute (NCI) to Raju S. Kucherlapati and Umar Mahmood, entitled: Mouse
Models for Human Cancer, 5U01CA084301-13. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: RK owns stock in, and is a paid member of the Board of Directors of AVEO Pharmaceuticals and Metamark Genetics. These entities have
interests in therapy development in areas related to the research. RK’s interests were reviewed and are managed by the Brigham and Women’s Hospital and
Partners’s HealthCare in accordance with their conflict of interest polices. does not alter the authors’ adherence to all PLOS ONE policies on sharing data and
materials.
* E-mail: mkucherlapati@partners.org
Introduction
Colorectal cancer (CRC) is the third most frequently diagnosed
cancer and cause of cancer mortality in the United States [1].
Therapeutic guidelines are based on TNM staging [2]. Stage I &
II (low risk) invasive tumors are removed surgically, and patients
with Stage II (high risk) & Stage III tumors are treated with
adjuvant therapy that includes FOLFOX (59-fluorouracil (5-FU)-
leucovorin-oxaliplatin), FLOX (bolus 5-FU-leucovorin-oxalipla-
tin), and CapeOx (capecitabine-oxaliplatin). The use of monoclo-
nal antibodies to VEGF-A (bevacizumab), EGFR (cetuximab &
panitumumab), and topoisomerase inhibitors (irinotecan) are
recommended for metastatic disease with appropriate genotype.
Because of the nonspecific nature of adjuvant therapies, their
side effects, and the actual percentage of patients who derive
benefit from them, it has long been hoped that the identification of
the progressive changes to the genome would lead to the
identification of points of intervention and the development of
specific inhibitors that would be less damaging and cause fewer
adverse events. Many of the major elements of the PI3K/AKT/
mTOR pathway have been found mutated or amplified in a wide
variety of tumor types [3] and for this reason PI3K inhibitors have
been sought after. NVP-BEZ235 [4], is a compound with dual
PI3K/mTOR inhibitor activity, that acts as an ATP competitor
and has been shown to significantly reduce tumor growth in a
number of human xenograft models [5–10] and PI3K driven lung
models [11–15]. The drug is currently involved in clinical trials for
solid tumors, breast cancer, endometrial cancer, and advanced
renal cell carcinoma [16].
In this study we use two conditional mouse models bearing
Msh2 mutation that develop spontaneous intestinal or colonic
tumors, to observe the effects of NVP-BEZ235. After identifying
MEK upregulation with subsequent MAPK increase in a
proportion of resistant intestinal adenocarcinomas, we have given
MEK inhibitor ADZ6244 [17], in combination therapy with
NVP-BEZ235. We follow effect of the drug(s) with both pathology,
and 18F FDG PET as evidenced by focal increase of the 18F FDG
that resolves with treatment. Molecular alterations in tumors of
several different components of the PI3K/AKT/mTOR and
MAPK/ERK signaling pathways as well as a metabolic indicator
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(PDPK1, synonymous with PDK1) have been examined, as has
apoptosis. These data indicate that NVP-BEZ235 has efficacy in a
proportion of tumors. However because of the possibility of
increased progression in a subset of resistant tumors, and the
diversity observed in signaling mechanisms, the drug should be
used in combination therapy with other specific pathway inhibitors
or conventional radiotherapy rather than alone when treating
mismatch repair (MMR) deficient colorectal cancer.
Materials and Methods
Ethics Statement
All procedures were in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institute of Health. All work reported here was
under protocol # 03390, approved by Harvard Medical School’s
Institutional Animal Care and Use Committee (IACUC). All
surgery was performed under anesthesia, and all efforts were made
to minimize suffering.
Msh2 LoxP/LoxP Cre Recombinase Transgenic Mouse Lines
In the first model the conditional Msh2 allele has been placed
under the control of the Villin-Cre transgene (B6.SJL-Tg (Vil-cre)
(97 Gum/J) [18,19]. The majority of these animals develop
adenocarcinomas of the small intestine.
The Generation of Large Intestinal Tumors from ApcLoxP/
LoxP Msh2 LoxP/LoxP Mouse Lines
In the second model large intestinal tumors were generated by
infusing Adenoviral-Cre (Ad5CMVcre; Gene Transfer Vector Core
University of Iowa) into the colons of mice bearing conditional
alleles for both Apc and Msh2 by laparotomy [20]. Animals were
prepped the day before surgery by denuding abdominal skin with
depilatory and replacing bedding with wire racks and fasting
overnight. The next day, after anesthetizing with 2% isoflurane, a
midline incision was made through the outer skin and the parietal
peritoneum. Both layers were retracted with a wire speculum. The
colon was clamped approximately three centimeters from the anus
Figure 1. LoVo Sensitivity to NVP-BEZ235,Msh2 & Apc Gene Rearrangement, Tumor & PET Scanning Grading Criteria. (A) The effect of
increasing amounts of NVP-BEZ235 on three human CRC cell lines is represented graphically. Percent viability =OD test sample/OD control
sample6100, the grey line represents 100%. (B) Pictorial representation of Grades 1-4 for intestinal and colonic tumors and the graded scoring system
used for PET scanning analysis of Villin-Cre Msh22/2mice treated with NVP-BEZ235 alone. Grade 1 PET scan images have no abnormal radiotracer (18F
FDG) uptake, Grade 2 have a single abnormal uptake focus, Grade 3 have multiple uptake foci or increased uptake in a loop of small intestine, and
Grade 4 have both multiple uptake foci and increased uptake in a loop of small intestine. (C) Msh2 gene rearrangement is identified by PCR analysis in
five colonic adenomas from Adenoviral-Cre Apc2/2 Msh22/2 mice. 1 An IHC image using anti Msh2 antibody on colonic epithelium from a C57Bl6/J
mouse. 2 A colonic adenoma from an Adenoviral-Cre Apc2/2 Msh22/2 mouse with complete Msh2 removal. 3 A colonic adenoma with partial Msh2
removal. (D) Apc gene rearrangement is identified by PCR analysis in five colonic adenomas. 1 Anti Apc antibody on wildtype (C57Bl6/J) colonic
epithelium. 2 Anti Apc IHC on a colonic adenoma.
doi:10.1371/journal.pone.0068817.g001
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and PBS used to wash feces from the interior. A custom built
catheter was used to deliver 100mL 0.05% trypsin to a specific area
of the colon defined by placement of a second clamp. After ten
minutes the second clamp was removed, the colon washed
extensively with PBS, and the interior abraded mechanically
using a miniature brush. A second catheter was placed and
localized with another clamp for Adenoviral-Cre delivery. Virus was
incubated in vivo for thirty minutes. Clamps were removed and the
abdominal wall was sutured closed in two layers, peritoneum
followed by the outer skin. Analgesics were administered after
surgery (Buprenorphine, 0.05–0.1 mg/kg/SQ Q 8–12 h).
In Vitro Drug Treatment of a Human CRC Cell Line
A CellTiter 96H Aqueous Assay (Promega) was used as described
previously [21] to determine cell line sensitivity to NVP-BEZ235.
Briefly, confluent plates of three human cell lines (HCT115,
SW480, & LoVo) obtained from the American Type Culture
Collection (ATCC) were treated with and suspended in RPMI-
1640 10% fetal calf serum/1% Penicillin (HCT115), Leibovitz’s L-
15 Medium (SW480), or F-12K Medium (LoVo). Cell viability was
determined by trypan blue exclusion test. Cells were plated in
quadruplicate in various concentrations for twenty-four hours.
CellTiter 96H Aqueous Assay (Promega) one step reagent was added
and after one hour the absorbance at 490 nm was read on an Elisa
Plate Reader to determine the linear range of cell growth for each
cell line. Cells were dispensed at this concentration subsequently to
determine the effect of various doses of NVP-BEZ235, also by
CellTiter 96H Aqueous Assay (Promega) one step reagent.
In Vivo Drug Treatment
NVP-BEZ235-NX (hereafter called NVP-BEZ235) was ob-
tained from Novartis Pharmaceuticals. Dry powder was dissolved
in N-Methyl-2-pyrrolidone (NMP) with brief heating, followed by
addition of PEG300 (1:9 NMP/PEG). Drug was placed into
solution immediately prior to delivery. Mice were weighed daily
and given 25 mg/kg NVP-BEZ235/NMP/PEG by gavage for
thirty days. ADZ4266 MEK 1&2 inhibitor was obtained from
Selleck Chemicals. Dry powder was dissolved in NMP and PEG
along with NVP-BEZ235. Mice were given 25 mg/kg ADZ4266
with NVP-BEZ235 five times per week by gavage for thirty days.
Histopathologic Analysis
Tumors of the Villin-Cre Msh22/2 GI tract were examined
systematically. After sacrifice the entire GI tract was removed. In
four cases (two each, drug/control) intestinal ‘‘Swiss roles’’ were
sectioned entirely, stained with Hematoxylin & Eosin (H&E), and
tumors counted. All other intestines were opened longitudinally.
Gross specimens were examined under a Zeiss dissecting
microscope and the number and location of the tumors recorded.
Tumors were fixed in 4% paraformaldehyde prior to being
Table 1. Occurrence of carcinomas in drug treated small intestines.
Treatment Sex n Total Grade 1 Grade 2 Grade 3 Grade 4
Genotype (Age/Mo) (M:F) Neoplastic n (%) n (%) n (%) n (%)
Events
Control/Vehicle treated
GVCM2CKO 2/2 (7–8) 4:8 12 371, 3 14 (37.9) 10 (27.0) 8 (21.6)2 5 (13.5)4
C57Bl6/J (4) 12 0 0 0 0 0
NVP-BEZ235 treated
GVCM2CKO2/2 (7–8) 9:3 12 271 10 (37.0) 11 (40.8) 0 (0)2 6 (22.2)
C57Bl6/J (4) 12 0 0 0 0 0
NVP-BEZ235 & ADZ6244
GVCM2CKO2/2 (7–8) 4:8 12 193 4(21.1) 2(10.5) 3(15.8) 10(52.6)4
1Multiplicity by Mann-Whitney test, Control?Drug P= 0.1005; Control .Drug P= 0.0503.
2Mann-Whitney Control?Drug P= 0.0145; Control .Drug P= 0.0072.
3Mann-Whitney test, Control?Drug P= 0.0121; Control .Drug P= 0.0006.
4Mann-Whitney test, Control?Drug P= 0.1600; Control .Drug P= 0.0800.
doi:10.1371/journal.pone.0068817.t001
Table 2. Tumor progression in drug treated small intestines.
Adenocarcinomas Control NVP-BEZ235 NVP-BEZ235
ADZ6244
Total found (Grades 3 & 4) 131 61 13
No. (%) with histological verification 13 (100) 6 (100) 13(100)
Grade 3: n (% of total) 8 (61.5)2,3 0 (0)2 3(23.1)3
Grade 4: n (% of total) 5 (38.5)2,3 6 (100)2 10(76.9)3
1Multiplicity by Mann-Whitney test. Control?Drug : P = 0.0387.
2Fisher exact test Grades 3 vs 4, Control?Drug : P = 0.0341.
3Fisher exact test Grades 3 vs 4, Control?Drug : P = 0.0302.
doi:10.1371/journal.pone.0068817.t002
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observed by pathology. Upon examination tumors were placed
into four categories. A ‘‘grade 1’’ lesion was defined as an
adenoma that floated above normal crypts, a ‘‘grade 2’’ lesion was
an adenoma that grew down to the submucosa without invasion, a
‘‘grade 3’’ lesion was an adenocarcinoma that invaded into the
mucosa and superficial muscularis, a ‘‘grade 4’’ adenocarcinoma
invaded deeply into the muscularis. All tumors were examined by
two individuals one of whom is an experienced veterinary
pathologist. The Fisher exact probability test was used for the
analysis of tumor incidence and tumor progression, and Mann-
Whitney test used for tumor multiplicity.
Positron Emission Tomography (PET) Imaging and
Optical Colonoscopy
PET imaging was done on a subset of animals before and after
drug delivery, for NVP-BEZ235 treated mouse models. The scan
and subsequent image analysis were performed using an eXplore
Vista microPET scanner (GE healthcare/Suinsa Medical Sys-
tems). All animals were fasted twelve to sixteen hours prior to
imaging. Anesthesia was induced using 5% isoflurane and oxygen
for 30 seconds, followed by 1.5% isoflurane and oxygen used for
maintenance during both injection and imaging. [18F]-Fluoro-2-
deoxy-D-glucose (18F FDG) was injected intravenously through
the tail vein with approximately 500 mCi of activity. Mice were not
anesthetized during the tracer accumulation period. Fifteen
minute static whole body scans were acquired one hour after
injection. The images were reconstructed using a two-dimensional
ordered-subset expectation maximization algorithm (2D-OSEM);
and correction was applied for attenuation and scatter. For mice
treated with NVP-BEZ235 and ADZ4266 combined therapy, CT-
PET images were obtained. PET imaging was acquired as
described above. CT scanning was acquired in standard resolu-
tion. Scan parameters were as follows: tube voltage 40 kVp, tube
current 140 mA, number of projections 360, number of shots 8,
axial field-of-view 80 mm. Scans were recorded without respira-
tory gating. Total scan duration was about 14 minutes. Image data
was reconstructed using FeldKemp algorithm.
For optical colonoscopy mice were anesthetized using 2%
isoflurane. The colon was washed with PBS to cleanse the bowel.
A custom made colonoscopy system was used as previously
described [22]. Air was carefully insufflated into the colon to allow
full visualization, but to avoid perforation. Endoscopic images and
Table 3. Wnt and PI3K signaling deregulation in MMR deficient tumors by immunohistochemistry relative to normal small
intestine and colon.
Antibody Site (n) Treatment Nuclear Nuclear & Membrane
N= total Cytoplasmic
(+)1 (–)1 (+)1 (–)1 (+)1 (–)1
n (%) n (%) n (%) n (%) n (%) n (%)
Msh2 N=133 Intestine (6) Untreated 0 (00) 6(100)
Intestine (7) NVP-BEZ235 0 (00) 7(100)
Msh2 N=133 Colon (10) Untreated 6(60)2 4(40)
Colon (3) NVP-BEZ235 1(33)2 2(67)
Apc N=84 Intestine (4) Untreated 1(25) 3(75)2
Intestine (4) NVP-BEZ235 0(00) 4(100)2
Apc N=54 Colon (2) Untreated 0(00) 2(100)
Colon (3) NVP-BEZ235 1(33) 2(67)
b-catenin N = 85 Intestine (4) Untreated 4(100) 0(00)
Intestine (4) NVP-BEZ235 4(100) 0(00)
b-catenin N = 55 Colon (2) Untreated 0(00) 2(100)
Colon (3) NVP-BEZ235 0(00) 3(100)
PTEN N= 96 Intestine (6) Untreated 3(50) 3(50)
Intestine (3) NVP-BEZ235 1(33) 2(67)
PTEN N= 66 Colon (4) Untreated 0(00) 4(100)2
Colon (2) NVP-BEZ235 0(00) 2(100)2
AKTpan N= 217 Intestine (16) Untreated 15(94)2 1(6)
Intestine (5) NVP-BEZ235 5(100)2 0(00)
AKTpan N= 57 Colon (3) Untreated 3(100) 0(00)
Colon (2) NVP-BEZ235 2(100) 0(00)
1(+) Increased (or equivalent) staining relative to normal mucosa (–) decreased staining.
2Nonuniform staining throughout the tumors.
3Removal of Msh2 is significantly better by Villin-Cre (small intestine) than by Adenoviral-Cre (colon),
Fisher exact P = 0.0026.
4Apc is removed significantly in both tumor types relative to normal mucosa, Fisher exact P,0.0001.
5b-catenin is significantly upregulated in adenocarcinomas of the small intestine but not in adenomas of the colon, Fisher exact P,0.0001.
6The difference in PTEN decrease between the small and large intestinal tumors is not significant, Fisher exact P = 0.0923.
7AKT is significantly upregulated in all tumors relative to normal mucosa, Fisher exact P,0.0001.
doi:10.1371/journal.pone.0068817.t003
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Figure 2. PET Scan Images Before and After NVP-BEZ235 Delivery in Two Mouse Models. (A) 18F FDG PET images of five Villin-Cre Msh22/
2 mice. Arrows indicate abnormal foci of increased uptake with overall significant difference in ‘‘before’’ and ‘‘after’’ images. Signal with ‘‘increased
uptake in loop’’ is seen in animal number 275 ‘‘before’’ image, no longer visible in the ‘‘after’’ drug treatment scan. (B) 18F FDG PET images of six
Adenoviral-Cre Apc2/2 Msh22/2 mice with no overall significant difference in ‘‘before’’ and ‘‘after’’ images. Arrows indicate abnormal foci of increased
uptake. Gross tumors obtained at autopsy are below the scans with images of tumors taken from colonoscopy videos made ‘‘before’’ and ‘‘after’’
treatment.
doi:10.1371/journal.pone.0068817.g002
Figure 3. PET Scan Images Taken Before and After Combined NVP-BEZ235 and ADZ4266 Delivery in Villin-Cre Msh22/2 Mice. In four
animals (A through D) treated with combined therapy, each had two tumors detected with 18F FDG CT-PET, the larger tumor is presented. (A) 1, 2, &
3, coronal, sagittal, and transverse images respectively are shown before drug treatment; (A) 4, 5, & 6, coronal, sagittal, and transverse images
respectively are shown after drug treatment demonstrating regression, with the red arrow indicating tumor position. (A) 7, largest gross tumor found
at necropsy (13.5 mg). (B) 1, 2, & 3 coronal, sagittal, and transverse images respectively are shown before drug treatment; (B) 4, 5, & 6, coronal,
sagittal, and transverse images respectively are shown after drug treatment. The red arrow marks the tumor found in the ‘‘before’’ image (tumor
regression), the green arrows in (B) 7, 8, 9, & 10/CT-PET, coronal, sagittal, transverse respectively, mark the development of a new resistant tumor. (B)
11, gross tumor found at necropsy (8 mg), (B) 12 a new drug resistant tumor (16 mg). (C) 1, 2, & 3, coronal, sagittal, and transverse images
respectively are shown before drug treatment; (C) 4, 5, & 6, coronal, sagittal, and transverse images respectively are shown after drug treatment with
tumor regression; (C) 7 shows the largest gross tumor at necropsy (205 mg). (D) 1, 2, & 3 coronal, sagittal, and transverse images are shown before
drug treatment; (D) 4, 5, & 6 coronal, sagittal, and transverse images shown after drug treatment with tumor regression in one tumor and tumor
development in the second (green arrows). (D) 7, largest gross tumor found at necropsy (230 mg).
doi:10.1371/journal.pone.0068817.g003
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videos were saved for later offline analysis by Image J software
[23].
Immunohistochemistry and Western Blotting
Five micrometer sections were cut from tissue embedded in
paraffin blocks for immunohistochemistry (IHC). Paraffin was
removed using xylene and sections rehydrated. Antigen retrieval
was done using 1X citrate buffer (pH6.0) (Zymed), and a Medical
Decloaking Chamber (Biocare Medical). Sections were ‘‘blocked’’
for peroxidase (Dako), serum (Normal Donkey/Rabbit serum),
and avidin and biotin (Vector Laboratories). Primary antibody was
applied overnight at 4uC, biotinylated secondary antibody for
thirty minutes at room temperature. A Vectastain ABC Kit
(Vector Laboratories), followed by Liquid+Substrate Chromogen
System (Dako) was used for antibody detection. Mayer’s Hema-
toxylin Solution and Scott’s Bluing Reagent were used for
counterstaining. The following antibodies were obtained from
Cell Signaling Technologies (Beverly, MA): AKTpan (cat.
no. 4691, 1:250 dilution), AKT-T308 (cat. no. 9275, 1:800),
AKT-S473 (cat. no. 4060, 1:50), pMEK1&2 (cat. no. 2338S,
1:50), p42p44MAPK (cat. no. 4377, 1:100 and cat. no. 4376,
1:400), pS6K (cat. no. 2215S, 1:1000), Msh2 (cat. no. 2017S,
1:200), mTOR (cat. no. 2983S, 1:50), p-mTOR (cat. no. 2971,
1:100). The following antibodies were obtained from Abcam
Biotechnologies (Cambridge, MA): PTEN (cat. no. AB32199,
1:250), PDPK1 (cat. no. AB109460, 1:250), pPDPK1 (cat. no.
AB31406, 1:250). Antibody to Cyclin D1 was from Thermo-
Scientific (cat. no. RM-9104-S1, 1:50 dilution). Antibody to Apc
was obtained from Gene Tex Inc. (cat. no. GTX15270, dilution
1:250). Antibody to b-catenin was obtained from Santa Cruz
Biotechnology, Inc. (cat. no. SC-1469-R, dilution 1:250). Tunel
and Caspase 3 analysis was done by the Special Immunohisto-
chemistry Core Facility.
For Western blot analysis, protein concentration was deter-
mined using Bio-Rad Protein Assay (Bio-Rad). Lysate containing
10 and 25 milligrams of protein were separated on a 10% SDS/
PAGE gel, and transferred to nitrocellulose membrane. After
blocking with 1% BSA, the membrane was probed with primary
antibody (two hours), and then by secondary antibody (one hour).
AmershamTM ECLTM Western blot reagents (GE Healthcare)
were used for detection. Some autoradiographs were screened by
densitometry using Image J software, with one way ANOVA used
Figure 4. Apc and b-catenin Levels are Altered in Villin-Cre Msh22/2 Adenocarcinomas. (A) 1 & 2 anti Apc IHC on normal small intestinal
sections. Panels 3 & 4 anti Apc IHC on adenocarcinomas from a Villin-Cre Msh22/2 mouse showing heterogeneous Apc expression with Apc loss in
the invasive portion of the tumor. (B) 1 & 2, anti b-catenin IHC on an adenocarcinoma section from a Villin-Cre Msh22/2 mouse. 3 Western blot
analysis of four Villin-Cre Msh22/2 adenocarcinomas showing increased b-catenin levels. (C) 1, 2, and 3, are IHC on normal mucosa using anti AKTpan,
anti AKT-S473, and anti AKT-T308 respectively. 4, 5, and 6, show IHC on intestinal adenocarcinomas using anti AKTpan, anti AKT-S473, and anti AKT-
T308 respectively. Western blot analysis of three adenocarcinomas showing increased total AKT and increased activated AKT (by phosphorylation)
relative to normal mucosa.
doi:10.1371/journal.pone.0068817.g004
NVP-BEZ235 and ADZ4266 Treatment of Msh22/2 Tumors
PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e68817
to determine significance. Most autoradiographs were judged
visually with no densitometry.
Results
Msh2 Deficient Human Colorectal Cancer Cell Line is
Sensitive to NVP-BEZ235
Several human colorectal cancer cell lines have been found to
be sensitive to NVP-BEZ235 however MSH2 has been intact in
those lines. To assess if MSH2 mutant human colon cancer cells
respond to this drug we examined LoVo (ATCC) and found this
line to be sensitive to the drug as well, as determined by
CellTiter96HAQueousAssay (Promega) (Fig. 1A).
Altered Tumor Biology by NVP-BEZ235 Alone and in
Combination Therapy with ADZ4266
Small Intestinal tumors. The effect of NVP-BEZ235 on
tumor biology in Villin-Cre Msh2LoxP/LoxP mice was studied. Mice
were treated with NVP-BEZ235 alone or with vehicle and
compared to normal C57Bl6/J mice. The effect of NVP-
BEZ235 in combined therapy with ADZ4266 was studied in an
additional group. Villin-Cre Msh2 LoxP/LoxP mice chosen for this
study were seven months of age (seven months being the median
survival rate for the colony) and clearly fecal occult blood (FOB)
positive ensuring that intestinal tumors were present. Tumors were
assigned a grade based on the degree of invasiveness. Grades 1 & 2
did not invade into the muscularis and were adenomas, while
grades 3 & 4 had muscularis invasion and were therefore
considered true adenocarcinomas (Fig. 1B). The results for tumor
incidence and progression are presented in Tables 1 and 2. A
decrease in the total neoplastic events was found in mice treated
with both NVP-BEZ235 alone, and in combination with
ADZ4266, the decrease was statistically significant in the
combined therapy group. In both cohorts the drug resistant
tumors are well advanced.
Colonic tumors. Adenoviral-Cre infusion into Msh2LoxP/LoxP
mice did not lead to tumor generation. We were able to induce
tumors in the large intestines of mice harboring conditional alleles
for both Apc and Msh2. Seventy-one percent of the animals
successfully infused had one to two large intestinal tumors, twenty-
two percent had three to six tumors, and seven percent had too
many tumors to count accurately. A size index for each tumor was
calculated using a software measurement tool (Zeiss) that gave a
range between three and twenty-three mm2. Colonic adenomas
were generally large. Gene rearrangement of Apc and Msh2 in
several of these tumors was assessed by Polymerase Chain
Reaction (PCR); and both genes were found to have been
inactivated (Fig. 1C & D). Examination of tumor sections with
IHC indicated that Msh2 was not completely removed uniformly
in all tumors (Table 3, Fig. 1C). Apc was removed uniformly in
colonic adenomas (Table 3, Fig. 1D). Whole genome sequencing
of colonic tumors (unpublished data) showed conclusively that
both the Apc and Msh2 were inactivated in adenocarcinomas.
Sixty-five neoplastic events were examined by pathology in
Table 4. Phosphorylation status of AKT and mTOR by immunohistochemistry.
Antibody Site (n) Treatment Nuclear Nuclear & Membrane
N= total Cytoplasmic
(+)1 (–)1 (+)1 (–)1 (+)1 (–)1
n (%) n (%) n (%) n (%) n (%) n (%)
AKT-T308 N=213 Intestine (13) Untreated 8(62)2 5(38)
Intestine (8) NVP-BEZ235 4(50) 4(50)
AKT-T308 N=133 Colon (10) Untreated 9(90) 1(10)
Colon (3) NVP-BEZ235 3(100) 0(00)
AKT-S473 N= 214 Intestine (14) Untreated 6(46)5 8(54)5
Intestine (7) NVP-BEZ235 0(00)5 7(100)5
AKT-S473 N= 134 Colon (11) Untreated 11(100)2 0(00)
Colon (2) NVP-BEZ235 2(100) 0(00)
mTOR N= 76 Intestine (4) Untreated 4(100) 0(00)
Intestine (3) NVP-BEZ235 3(100) 0(00)
mTOR N= 56 Colon (3) Untreated 0(00) 3(100)
Colon (2) NVP-BEZ235 0(00) 2(100)
p-mTOR N=67 Intestine (3) Untreated 3(100)2 0(00)
Intestine (3) NVP-BEZ235 3(100)2 0(00)
p-mTOR N=57 Colon (3) Untreated 0(00) 3(100)
Colon (2) NVP-BEZ235 0(00) 2(100)
1(+) Increased (or equivalent) staining relative to normal mucosa (2) decreased staining.
2Nonuniform staining throughout the tumors.
3AKT-T308 is significantly downregulated in intestinal adenocarcinomas relative to colonic adenomas,
4AKT-S473 is significantly downregulated in intestinal adenocarcinomas relative to colonic adenomas, Fisher exact P,0.0001.
5AKT-S473 is downregulated in drug treated intestinal tumors relative to untreated intestinal tumors (staining judged more or less intense relative to normal crypts)
Fisher exact P = 0.0553.
6mTOR significantly upregulated in adenocarcinomas of the small intestine relative to adenomas of the colon, Fisher exact P = 0.0013.
7p-mTOR localizes subcellular to the nucleus in adenocarcinomas and the cytoplasm of adenomas, Fisher exact P = 0.0022.
doi:10.1371/journal.pone.0068817.t004
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untreated mice. Tumors from these animals were placed into the
same groupings (groups 1–4) as used for small intestinal tumors
(Fig. 1B). Seventy-two percent of the neoplastic events were judged
to be Grade 1, seventeen percent Grade 2, nine percent Grade 3,
and two percent Grade 4. Adenomas made up 89% of the
neoplastic events with 11% designated as adenocarcinomas. Seven
mice were treated with NVP-BEZ235 and compared to two
animals treated with vehicle. All of these mice were found to have
drug resistant Grade 1 adenomas.
PET Scans and Optical Colonoscopy Support Pathologic
Findings in Both Mouse Models
Small intestinal tumors. Because tumors occur predomi-
nantly in the small intestine in Villin-Cre Msh2LoxP/LoxP mice optical
Figure 5. Intestinal Adenocarcinomas Resistant to NVP-BEZ235 Have Variable Levels of activated AKT, MAPK, and Apoptosis. (A) 18F
FDG PET image of a Villin-Cre Msh22/2 mouse with NVP-BEZ235 resistant tumor with cyst (arrow). (B) IHC on section from tumor shown in panel ‘‘A’’
showing loss of PTEN in invasive cells. (C) IHC with anti AKT (AKTpan). (D) Gross tumor with cyst (E & F) IHC with anti AKT-S473 and anti AKT-T308,
respectively. (G) Induction of apoptosis as seen with Tunel analysis (confirmed using anti Caspase 3). (H) IHC showing p42p44 MAPK upregulation (I)
Activated p-mTOR is decreased in the cytoplasm and increased in the nucleus of the invasive portion of the adenocarcinoma. (J) Western blot analysis
on NVP-BEZ235 resistant intestinal tumors (three separate blots presented). AKT protein levels differ between treated tumors (K) Western blot analysis
showing AKT phosphorylation at S473 in drug resistant intestinal tumors.
doi:10.1371/journal.pone.0068817.g005
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colonoscopy was not feasible, and they were screened with 18F
FDG PET or CT-PET scans. A graded scoring system for PET
scan signals from mice treated with NVP-BEZ235 alone (1
through 4) was developed and applied (Fig. 1B). Grade 1 had no
abnormal radiotracer (18F FDG) uptake. Grade 2 had a single
abnormal uptake focus. Grade 3 had multiple uptake foci or
increased uptake in a loop of small intestine (Fig. 2A, Fig S1A),
and Grade 4 had both multiple uptake foci and increased uptake
in a loop of small intestine. We also examined two Apc1638N mice
that have a phenotype of intestinal adenomas with 18F FDG PET
and found only discreet signaling around the intestinal lesions (Fig.
S1B), suggesting the more progressed tumors were responsible for
the visualized ‘‘loop’’ signal. Comparison of a group of Villin-Cre
Msh2LoxP/LoxP mice with only PET ‘‘after’’ drug/placebo images
did not reveal a significant difference between drug and control
groups (P= 0.119 by Mann-Whitney U test). However in a
comparison of a second group of animals with both ‘‘before’’ and
‘‘after’’ drug/placebo delivery PET scan images, radiotracer
uptake grades were pooled and the scores of ‘‘before’’ and ‘‘after’’
images judged significantly different (P = 0.031, independent
samples; P= 0.034 drug treatment group) (Fig. 2A). In general,
pathology and PET scans were in agreement for adenocarcinomas
in the NVP-BEZ235 alone study. The intestines of four mice used
for PET scans were placed into ‘‘Swiss rolls’’ and sectioned serially
in their entirety. Very small early intestinal polyps were detected in
this way and included in the pathology counts. These early polyps
were not always picked up with PET scanning, potentially due to
expected volume averaging of the imaging.
For the NVP-BEZ235/ADZ4266 group of mice (Fig. 3 A–D) a
standardized uptake value (SUV) for pre and post therapy was
obtained that represented the ratio of signal obtained from the
tumor and the cerebellum. The pre and post SUV maximum
mean value for all tumors was 1.2560.16 and 0.8960.08
respectively (Paired t-test P= 0.012). Pre and post SUV mean
value for all tumors was 0.760.05 and 0.5860.04 (P = 0.025). Pre
and post mean volume (cc) 0.3260.1 and 0.07560.03 (P= 0.045).
Seventy-five percent of the tumors treated with combined therapy
showed significant regression. The development of two resistant
tumors was documented (Fig. 3B and D).
Colonic tumors. Adenomas of the large intestine created by
Adenoviral-Cre infusion were examined both by optical colonoscopy
(Fig. 2B, and Fig. S1C) and also by PET scan before and after
drug/placebo delivery for the NVP-BEZ235 alone study (Fig. 2B).
All animals, drug and control treated, had adenomas before and
Table 5. MAPK/ERK signaling and metabolic deregulation by immunohistochemistry.
Antibody Site (n) Treatment Nuclear Nuclear & Membrane
N= total Cytoplasmic
(+)1 (–)1 (+)1 (–)1 (+)1 (–)1
n (%) n (%) n (%) n (%) n (%) n (%)
pMEK1&23 N = 11 Intestine (8) Untreated 8(100) 0(00)
Intestine (3) NVP-BEZ235 3(100) 0(00)
pMEK1&23 N= 5 Colon (3) Untreated 3(100) 0(00)
Colon (2) NVP-BEZ235 2(100) 0(00)
p42p44MAPK4,5 N = 38 Intestine (21) Untreated 16(76)2 5(24)2
Intestine (17) NVP-BEZ235 16(94)2 1(6)2
p42p44MAPK4,5 N = 13 Colon (10) Untreated 1(10)2 9(90)2
Colon (3) NVP-BEZ235 1(33)2 2(67)2
pS6K N=116 Intestine (8) Untreated 8(100)2 0(00)
Intestine (3) NVP-BEZ235 3(100)2 0(00)
pS6K N=56 Colon (3) Untreated 3(100)2 0(00)
Colon (2) NVP-BEZ235 2(100)2 0(00)
PDPK1 N=77 Intestine (4) Untreated 4(100) 0(00)
Intestine (3) NVP-BEZ235 3(100) 0(00)
PDPK1 N=57 Colon (3) Untreated 3(100)2 0(00)
Colon (2) NVP-BEZ235 2(100)2 0(00)
pPDPK1 N= 78 Intestine (4) Untreated 4(100) 0(00)
Intestine (3) NVP-BEZ235 3(100) 0(00)
pPDPK1 N= 58 Colon (3) Untreated 3(100)2 0(00)
Colon (2) NVP-BEZ235 2(100)2 0(00)
1(+) Increased (or equivalent) staining relative to normal mucosa (2) decreased staining.
2Nonuniform staining throughout the tumors.
3pMEK1&2 is significantly upregulated in all tumors relative to normal mucosa, Fisher exact P,0.0001.
4p42p44MAPK is significantly upregulated in all tumors relative to normal mucosa, Fisher exact P,0.0001.
5p42p44MAPK significantly upregulated in adenocarcinomas of the small intestine relative to adenomas of the colon, Fisher exact P,0.0001.
6pS6K is upregulated (nonuniform staining) in all tumors relative to normal mucosa, Fisher exact P,0.0001.
7PDPK1 is upregulated in all tumors relative to normal mucosa, Fisher exact P,0.0001.
8pPDPK1 is significantly upregulated and membrane associated in all tumors relative to normal mucosa, Fisher exact P,0.0001.
doi:10.1371/journal.pone.0068817.t005
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Table 6. Cell cycle and apoptosis deregulation in MMR deficient tumors by immunohistochemistry.
Antibody Site (n) Treatment Nuclear Nuclear & Membrane
N= total Cytoplasmic
(+)1 (–)1 (+)1 (–)1 (+)1 (–)1
n (%) n (%) n (%) n (%) n (%) n (%)
Cyclin D1 N= 81 Intestine (5) Untreated 5(100) 0(00)
Intestine (3) NVP-BEZ235 3(100) 0(00)
Cyclin D1 N= 61 Colon (3) Untreated 3(100) 0(00)
Colon (3) NVP-BEZ235 3(100) 0(00)
Tunel N = 92 Intestine (5) Untreated 0(00)3 5(100)3
Intestine (4) NVP-BEZ235 1(25)3 3(75)3
Tunel N = 0 Colon (0) Untreated n.d.4 n.d.
Colon (0) NVP-BEZ235 n.d. n.d.
Caspase 3 N=82 Intestine (5) Untreated 2(40)5 3(60)5
Intestine (3) NVP-BEZ235 2(67)5 1(33)5
Caspase 3 N=0 Colon (0) Untreated n.d. n.d.
Colon (0) NVP-BEZ235 n.d. n.d.
1Cyclin D1 is up-regulated relative to normal mucosa in the nucleus of all adenocarcinomas and adenomas, Fisher exact P,0.0001.
2Not significantly different, Fisher exact P = 0.30.
3Not significantly different, Fisher exact P = 0.40.
4‘‘n.d.’’ not determined.
5Not significantly different, Fisher exact P = 0.50.
doi:10.1371/journal.pone.0068817.t006
Figure 6. Molecular Analysis of Untreated and Drug Treated Tumors. (A and B) Western blot analysis of colonic adenomas (CT1–8) for total
AKT levels (AKTpan), AKT activated by phosphorylation, and activated MAPK (‘‘M’’ lanes, normal mucosa). (C) Small intestinal tumors examined for
activated MAPK by Western blot analysis and IHC (left panel normal mucosa, right panel an invasive adenocarcinoma). (D) Western blot analysis of
small intestinal adenocarcinomas and IHC using anti pPDPK1 showing increased membrane associated staining (left panel(s) normal mucosa, right
panel an intestinal adenocarcinoma). (E) Western blot analysis and IHC for Cyclin D1 (left is normal mucosa, right is invasive adenocarcinoma).
doi:10.1371/journal.pone.0068817.g006
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after drug/placebo treatment. Tumors in the control group
exhibited progression. Evidence of partial regression was found
in some NVP-BEZ235 treated animals, however this was not
found significant. The pre and post SUV maximum mean value
for these colonic tumors was 1.3660.36 and 1.1560.28 respec-
tively (Paired t-test P = 0.61). The pre and post SUV mean values
were 0.6660.17 and 0.5260.19 respectively (P = 0.36). Pre and
post volumes (cc) were 0.1260.99 and 0.0660.05 (P= 0.35).
Colonic tumor model images, while exhibiting 18F FDG uptake
beyond the lesions, consistently had more discreet signals than the
images from the intestinal model. While the apparent lack of drug
efficacy correlated with decreased tumor progression seen in this
model, the lack of significant decrease in values may have been
due to sample size and a reflection of the relative difficulty in
making the mice of that model.
Wnt and PI3K/AKT/mTOR Signaling Pathways are
Upregulated in MMR Deficient Tumors
Apc and b-catenin levels were examined in both mouse models.
Apc was downregulated in the invasive regions of small intestinal
tumors as shown by IHC, and b-catenin uniformly upregulated as
shown by IHC and Western blot analysis (Table 3, Fig. 4A and B).
Taken together, these findings are consistent with a large body of
evidence that Wnt signaling pathway is deregulated in CRC.
To implicate NVP-BEZ235 as a rationale drug of choice for
therapy in MMR deficient tumors, we examined specific
alterations in AKT signaling pathway using IHC and/or Western
blot analysis. AKT itself is a downstream effector of PI3K, and
AKT phosphorylation in tumors has been associated with both
poor and favorable outcomes in CRC [24]. In both our models
total AKT levels (AKTpan) were found upregulated (Table 3,
Fig. 4C). A proportion of tumors in both models had AKT
phosphorylation at S473 and T308 (Table 4, Fig. 4C). The tumor
suppressor PTEN that leads to upregulation of AKT was also
found inactivated in a proportion of both tumor types (Table 3).
Drug resistant tumors in both models were also examined by
IHC (Tables 3–6, Fig. 5A–I) and Western blot analysis (Fig. 5 J &
K, Fig. 6 A & B) in an initial attempt to explore drug efficacy, and
trends in pathways between treated and untreated tumors. Overall
IHC did not give definitive results when examining drug versus
untreated groups. We did find by IHC that drug resistant tumors
of the small intestine with increased total AKT had lowered AKT
phosphorylation at S473 relative to untreated tumors, implying
drug efficacy in some tumors but not in others (Table 4, Fig. 5K).
We are assessing the basis for the difference. We find that p-
mTOR known to be inhibited by NVP-BEZ235, localized to the
nucleus of small intestinal adenocarcinomas and to the cytoplasm
of adenomas independent of treatment (Table 4).
pMEK1&2, p42p44 MAPK, pS6K, PDPK1, Cyclin D1,
Apoptosis Alterations in Tumors
pMEK1&2 were found significantly upregulated in all tumors
relative to the normal mucosa by IHC (Table 5). This was true for
p42p44MAPK as well, with confirmation by Western blot analysis
in a proportion of intestinal tumors (Table 5, Fig. 6C). pS6K levels
were also found upregulated (Table 5, Fig. 6D). The data are in
correlation with the finding that MEK inhibitor ADZ4266 in
combination with NV-BEZ235 was an effective drug regimen for a
majority of intestinal tumors. Combination therapy has not yet
been applied to the Adenoviral-Cre model.
The metabolic regulator PDPK1 can activate S6K by
phosphorylation. All tumors examined with IHC had high PDPK1
signal localizing to the membrane with evidence of modification
by phosphorylation in Western blot analysis (Table 5, Fig. 6D). All
tumors showed upregulation of Cyclin D1 in the nucleus of
invasive cells (Table 6). IHC results were confirmed with Western
blot analysis (Fig. 6E).
Intestinal tumors, untreated or drug resistant, were examined
for apoptosis using both TUNEL analysis and IHC with antibody
to Caspase 3. We found apoptosis in some tumors (Table 6) but
not others.
Discussion
Human colorectal tumors can be classified as having high or low
mutation rates [25]. About fifteen percent of CRC’s have high
mutation frequencies with microsatellite instability, a feature
known to be associated with defects in DNA mismatch repair
resulting from mutation in MLH1, MSH2, PMS1, PMS2, or
MSH6 [26]. We have treated MMR deficient murine adenocar-
cinomas of the intestine and adenomas of the colon with NVP-
BEZ235, a PI3K/mTOR inhibitor, as a proportion of these
tumors have alterations in the PI3K/AKT/mTOR signaling
pathway. Upon identifying alterations to MAPK signaling
pathway we have continued gene directed therapy using MEK
inhibitor ADZ4266 in combination with NVP-BEZ235.
Both of the mouse models tested haveMsh2 deficiency, although
the intestinal model has under lying molecular events that better
mimic the sporadic human condition because Msh2 deficiency acts
as the driver for Apc loss. When the Villin promoter is in control of
Cre recombinase the enzyme is constitutively expressed throughout
development and in the adult gastrointestinal tract. The tumors
are restricted to the small intestine. In the second model, Adenoviral-
Cre infusion during laparotomy into the distal colons of three
month old double homozygous ApcLoxP/LoxP Msh2 LoxP/LoxP mice
enables reliable spontaneous adenoma formation in the large
intestine that can be subsequently followed by endoscopy and
other types of imaging without sacrificing the mice. The advantage
to this model is that the tumors are induced by a somatic event and
are located in the large intestine at the site of Adenoviral-Cre
infusion. Both models provide different perspectives when
evaluating the efficacy and safety of a cancer drug and in total
give information that can help evaluate a drug for clinical use.
Using a rational approach to cancer therapy in our models we
have shown that multiplicity and progression of tumors is affected
by NVP-BEZ235 therapy alone and in combination with
ADZ4266. Through imaging and pathology we have found
evidence that some tumors were responsive to the drugs while
others were resistant, suggesting the neoplastic pathways used by
all of the tumors were not the same. The hypermutation
phenotype associated with MMR deficiency may explain this
heterogeneity. After NVP-BEZ235 treatment a proportion of
resistant tumors are found to have upregulated MAPK signaling.
This is in agreement with reports that suggest conditions of
mTOR inhibition, as would occur with NVP-BEZ235 treatment,
activate MAPK through RAS [27] and that cross talk exists
between MAPK/ERK and PI3K/AKT/mTOR pathways. The
addition of a MEK inhibitor in combined therapy with NVP-
BEZ235 returns MAPK levels to predrug treatment levels in all
tumors tested, as seen by Western blot analysis, but does not
entirely eliminate the tumor phenotype. We have not yet
investigated the mechanisms of resistance to combined therapy.
pS6K was heterogeneously upregulated in all tumors including
NVP-BEZ235 treated tumors, suggesting that if a negative
feedback inhibition loop with MAPK signaling pathway exists it
was impaired in these tumors. Since PDPK1 can also activate S6K
[28] we examined tumors from both groups for activated PDPK1
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(pPDPK1), and found it highly upregulated by phosphorylation
and recruited to the membrane. PDPK1 is thought to be a master
regulator of both the AKT and MAPK pathways [29,30], and
may compensate for loss of PI3K when under selective pressure
from the drug. PDPK1 is also involved in glucose metabolism and
a body of still controversial evidence links the switch towards
aerobic glycolysis in tumor cells with the upregulation of HIF-1a
target genes (e.g.PDPK1, Glut1, Pfk1, Ldha) under the control of
the histone deacetylase SIRT6 [31,32]. Upregulation of phospho-
glycerate dehydrogenase (PHGDH) as judged by IHC, an enzyme
upstream of serine biosynthesis also occurs in our intestinal tumors
(unpublished data) and to a lesser extent in the colonic adenomas.
Serine is the precursor to glycine that is essential for purine
biosynthesis thought to supply ATP synthesis in the absence of the
Tricarboxylic Acid Cycle (TCA) cycle [33,34], and thought to
supply the increased need for Phosphatidylserine (PS) in mem-
brane biogenesis of rapidly proliferating tumor cells. It is being
rediscovered as a potential target for intervention, having been
proposed as such for many years [35]. New inhibitors are
becoming available for targeting metabolism, and because all
adenocarcinomas seem to have the metabolic shift towards aerobic
glycolysis it may also be a good point of intervention.
Supporting Information
Figure S1 Additional PET Scan and Colonoscopy Imag-
es. (A) 18F FDG PET image of a Villin-Cre Msh22/2 mouse
showing increased uptake in morphologically normal intestine
proximal to an adenocarcinoma. (B) PET scan images of a mouse
with Apc1638N genotype using 18F FDG tracer, an intestinal lesion
(adenoma) is indicated by a yellow arrow in the anterior middle
abdomen. There is physiologic 18F FDG uptake in the heart
(brown arrow) and in brown fat (red arrow), and thoracic
musculature (blue arrow). (C) Optical colonoscopy on mice with
Apc loxP/LoxP Msh2 loxP/loxP genotype, shows tumors before and after
NVP-BEZ235 drug treatment.
(TIF)
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